POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good but the bar is very high nowadays in PsA Questions splicing through depth of response Definitely will find a place in therapy, but where? #ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN

POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk 16 to 52 Pooled analysis wk 16 ACR 20 54% vs. 31% Enthesitis reduction LEI 52% vs. 45% Dactylics resolution 58% vs. 44% POETYK-PsA 1 Wk 52 ACR 20 63% ACR50 44% PASI https://t.co/LYJbU8fYwI

In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ

Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8

PD-1 agonist as an induction therapy in refractory RA?? Rosnilimab ph2b: - still responding 3mo after Rx stopped - no difference between type of prior b/tsDMARD failure - safety here looks good *so far* A lot of cautious excitement in the room for this #ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N

A new approach in RA: Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety. @RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C

#ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest https://t.co/MecTYMpH0o

Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients. 41% prior bDMARD. 69% CDAI LDA week 14. Week 12 ACR20 70%, ACR50 40%, ACR70 21%. @RheumNow #ACR25 Abstr#LB19 https://t.co/479q6COWvk

b/tsDMARD in RA + CKD (eGFR <60) From >12K pts in CorEvitas: - overall effective but 30% ↓ CDAI-emission (HR 0.71) - Findings consistent across TNFi, IL-6i, ABA BCDT, JAKi @RheumNow #ACR25 A#2640 https://t.co/UOP9ejZKoA

🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/beh3bEL8fs